Trial Profile
A 24-week, Randomized, Open-label, Parallel Group Multinational Comparison of Lantus® (Insulin Glargine) Given in the Morning as Once-a-day Basal Insulin Versus NPH Insulin, in Children With Type 1 Diabetes Mellitus Aged at Least 1 Year to Less Than 6 Years - PRESCHOOL
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2018
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin suspension isophane
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRESCHOOL
- Sponsors Sanofi
- 05 Oct 2012 Results of a pharmacokinetic analysis of insulin glargine (n=61) presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 15 Mar 2012 This trial is recruiting in Spain as reported by European Clinical Trials Database (EudraCT2009-011231-12).
- 04 Apr 2011 Actual end date (1 Mar 2011) added as reported by ClinicalTrials.gov.